BiotechTube

Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic Emulsion

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cataract

Conditions

Cataract

Trial Timeline

Dec 1, 2020 → Oct 24, 2022

NCT ID
NCT04687800

About Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic Emulsion

Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic Emulsion is a approved stage product being developed by Ocular Therapeutix for Cataract. The current trial status is terminated. This product is registered under clinical trial identifier NCT04687800. Target conditions include Cataract.

What happened to similar drugs?

9 of 19 similar drugs in Cataract were approved

Approved (9) Terminated (2) Active (8)
✅Prednisolone acetateNovartisApproved
✅Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
✅Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
✅Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
✅Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
✅Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
✅Dexamethasone + Prednisolone Acetate OphthalmicEyePoint PharmaceuticalsApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04687800ApprovedTerminated

Competing Products

20 competing products in Cataract

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
40
ISV-303 + Bromday™Sun PharmaceuticalPhase 2
35
ISV-305Sun PharmaceuticalPhase 3
40
DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
40
Prednisolone acetateNovartisApproved
43
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
37
Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3
34
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]Ocular TherapeutixPhase 2/3
24
Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
37
DexycuEyePoint PharmaceuticalsPhase 3
26
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
37
DexycuEyePoint PharmaceuticalsPhase 3
26
DEXYCU (dexamethasone intraocular suspension) 9%.EyePoint PharmaceuticalsPre-clinical
20
Dexamethasone + Prednisolone Acetate OphthalmicEyePoint PharmaceuticalsApproved
44
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 1/2
30
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
OMS302 + OMS302-PE + VehicleOmeros CorporationPhase 1/2
26